These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 8058127

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist.
    Brun P, Leonetti M, Sotty F, Steinberg R, Soubrié P, Renaud B, Suaud-Chagny MF.
    J Neurochem; 2001 Jun; 77(6):1542-52. PubMed ID: 11413237
    [Abstract] [Full Text] [Related]

  • 3. Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens.
    Brun P, Steinberg R, Le Fur G, Soubrié P.
    J Neurochem; 1995 May; 64(5):2073-9. PubMed ID: 7722490
    [Abstract] [Full Text] [Related]

  • 4. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat.
    Kalivas PW, Burgess SK, Nemeroff CB, Prange AJ.
    Neuroscience; 1983 Mar; 8(3):495-505. PubMed ID: 6406930
    [Abstract] [Full Text] [Related]

  • 5. The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area.
    Leonetti M, Brun P, Sotty F, Steinberg R, Soubrié P, Bert L, Renaud B, Suaud-Chagny MF.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):427-33. PubMed ID: 12070755
    [Abstract] [Full Text] [Related]

  • 6. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing.
    Kalivas PW, Nemeroff CB, Prange AJ.
    Neuroscience; 1984 Apr; 11(4):919-30. PubMed ID: 6738859
    [Abstract] [Full Text] [Related]

  • 7. Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems.
    Azzi M, Betancur C, Sillaber I, Spanagel R, Rostène W, Bérod A.
    J Neurochem; 1998 Sep; 71(3):1158-67. PubMed ID: 9721741
    [Abstract] [Full Text] [Related]

  • 8. In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and D-Trp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat.
    Ford AP, Marsden CA.
    Brain Res; 1990 Nov 26; 534(1-2):243-50. PubMed ID: 2073584
    [Abstract] [Full Text] [Related]

  • 9. Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system.
    Alburges ME, Hoonakker AJ, Hanson GR.
    Eur J Pharmacol; 2007 Nov 14; 573(1-3):124-32. PubMed ID: 17689525
    [Abstract] [Full Text] [Related]

  • 10. Enhanced dopamine metabolism in accumbens leads to motor activity and concurrently to increased output from nondopamine neurons in ventral tegmental area and substantia nigra.
    Olds ME.
    Physiol Behav; 1992 Jan 14; 51(1):39-50. PubMed ID: 1311110
    [Abstract] [Full Text] [Related]

  • 11. Mesolimbic dopamine mediates gastric mucosal protection by central neurotensin.
    Xing LP, Balaban C, Seaton J, Washington J, Kauffman G.
    Am J Physiol; 1991 Jan 14; 260(1 Pt 1):G34-8. PubMed ID: 1899007
    [Abstract] [Full Text] [Related]

  • 12. Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats.
    Poncelet M, Souilhac J, Gueudet C, Terranova JP, Gully D, Le Fur G, Soubrié P.
    Psychopharmacology (Berl); 1994 Oct 14; 116(2):237-41. PubMed ID: 7862953
    [Abstract] [Full Text] [Related]

  • 13. Neurotensin antagonist acutely and robustly attenuates locomotion that accompanies stimulation of a neurotensin-containing pathway from rostrobasal forebrain to the ventral tegmental area.
    Reynolds SM, Geisler S, Bérod A, Zahm DS.
    Eur J Neurosci; 2006 Jul 14; 24(1):188-96. PubMed ID: 16882016
    [Abstract] [Full Text] [Related]

  • 14. Microinjection of neurotensin into the ventral tegmental area produces hypothermia: evaluation of dopaminergic mediation.
    Kalivas PW, Nemeroff CB, Miller JS, Prange AJ.
    Brain Res; 1985 Feb 11; 326(2):219-27. PubMed ID: 2982460
    [Abstract] [Full Text] [Related]

  • 15. Hippocampal signal transmission to the pedunculopontine nucleus and its regulation by dopamine D2 receptors in the nucleus accumbens: an electrophysiological and behavioural study.
    Yang CR, Mogenson GJ.
    Neuroscience; 1987 Dec 11; 23(3):1041-55. PubMed ID: 2963972
    [Abstract] [Full Text] [Related]

  • 16. Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens.
    Laitinen K, Crawley JN, Mefford IN, De Witte P.
    Brain Res; 1990 Jul 23; 523(2):342-6. PubMed ID: 1698106
    [Abstract] [Full Text] [Related]

  • 17. Dopamine-dependent contralateral circling induced by neurotensin applied unilaterally to the ventral tegmental area in rats.
    Holmes LJ, Wise RA.
    Brain Res Bull; 1985 Nov 23; 15(5):537-8. PubMed ID: 4063843
    [Abstract] [Full Text] [Related]

  • 18. Neurotensin causes a greater increase in the metabolism of dopamine in the accumbens than in the striatum in vivo.
    Rivest R, Jolicoeur FB, Marsden CA.
    Neuropharmacology; 1991 Jan 23; 30(1):25-33. PubMed ID: 2046877
    [Abstract] [Full Text] [Related]

  • 19. Regulation of neurotensin receptor mRNA expression by the receptor antagonist SR 48692 in the rat midbrain dopaminergic neurons.
    Yamada M, Bolden-Watson C, Watson MA, Cho T, Coleman NJ, Yamada M, Richelson E.
    Brain Res Mol Brain Res; 1995 Nov 23; 33(2):343-6. PubMed ID: 8750895
    [Abstract] [Full Text] [Related]

  • 20. Neuromedin N mimics the actions of neurotensin in the ventral tegmental area but not in the nucleus accumbens.
    Kalivas PW, Richardson-Carlson R, Duffy P.
    J Pharmacol Exp Ther; 1986 Sep 23; 238(3):1126-31. PubMed ID: 3755755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.